Drugs / BI 1839100
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06572111 | Sep → Oct 2024 | — | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1 | NCT05934955 | Jul → Sep 2023 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05738291 | May 2023 → Jun 2024 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05354453 | May 2022 → Jun 2023 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06360094 | Aug 2024 → Sep 2025 | idiopathic pulmonary fibrosis, pulmonary fibrosis | Boehringer Ingelheim | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 1839100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06360094 ↗ |
| Route | Oral | “Single Rising Oral Doses of BI 1839100” NCT05354453 ↗ |